Research Article

Anemia response to Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) versus Epoetin Alfa (Eprex) in patients with chronic Kidney disease on Hemodialysis

Alaa K Dhayef*, Jawad K Manuti and Abdulwahab S Abutabiekh

Published: 05 September, 2017 | Volume 1 - Issue 1 | Pages: 041-047

Objective: Anemia, a common complication of chronic kidney disease, usually develops because of erythropoietin deficiency. Maintaining target hemoglobin (Hb) with minimal variability is a challenge in hemodialysis (HD) patients. The aim of this study is to compare the long- and short-acting erythropoietin erythropoietin stimulating agents such as Mircera and Eprex in achieving these targets.

Results: The response rate in the evaluation period was higher in patients treated with methoxypolyethylene glycol-epoetin beta (Mircera) than with epoetin (Eprex) alfa: 36 of 50 (72%) mean Hb concentration (10.51g/dl) versus 29 of 50 (58%) mean Hb concentration (9.81), with statistically significant p-value <0.0001.

Conclusion: Treatment with (Mircera) administered intravenously once monthly was superior to treatment with (Eprex) administered subcutaneously three times weekly for maintaining haemoglobin concentrations in patients with chronic kidney disease on hemodialysis.

Read Full Article HTML DOI: 10.29328/journal.jcn.1001006 Cite this Article Read Full Article PDF


Mircera; Eprex; Hemodialysis


  1. Anía BJ, Suman VJ, Fairbanks VF, Rademacher DM, Melton LJ. Incidence of anemia in older people: an epidemiologic study in a well defined population. J Am Geriatr Soc. 1997; 45: 825-831. Ref: https://goo.gl/tCC1mN
  2. Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, et al. Definition and classification of chronic kidney disease: A position statement from kidney disease improving global outcomes (KDIGO). Kidney Int. 2005; 67: 2089-2100. Ref.: https://goo.gl/i6g9Qi
  3. Kidney Disease Improving Global Outcomes. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: Summary of Recommendation Statements. Kidney Int. 2013; 84: 5-14.
  4. Okada TS, Yanai MK, Takahashi S. The Kidney Early Evaluation Program (KEEP) of Japan: Results from the initial screening period. Kidney Int. 2010; 77: 17-23. Ref.: https://goo.gl/HDm4cr
  5. Goddard J, Turner A. Kidney and urinary tract disease, Davidson’s Principles and Practice of Medicine. 22th ed. NewYourk: Brian R. Walker Elsevier. 2014; 488.
  6. Bargman JM, Karl S, Joanne M. Chronic kidney disease, disorders of the kidney and urinary tract, Dennis L. Stephen L, (editors). Harrison principle of internal medicine. 19th edition. 2015; 1818-1826. Ref.: https://goo.gl/rC3dz8
  7. Macdougall I, Eckardt K. Novel strategies for stimulating erythropoiesis and potential new treatment for anemia. Lancet. 2006; 368: 947-953. Ref.: https://goo.gl/Fh2LNP
  8. Strippoli G, Manno C, Schena F, Craig JC. Haemoglobin and haematocrit targets for the anaemia of chronic renal disease. Cochrane Database Syst Rev. 2003; 1. Ref.: https://goo.gl/bs1DTk
  9. Collins A, Li S, Peter W, Ebben J, Roberts T, et al. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol. 2001; 12: 2465-2473. Ref.: https://goo.gl/y5FiDP
  10. Xue JL, St Peter WL, Ebben JP, Everson SE, Collins AJ. Anemia treatment in the pre-ESRD period and associated mortality in elderly patients. Am J Kidney Dis. 2002; 40: 1153-1161. Ref.: https://goo.gl/i8MsZD
  11. Besarab A, Bolton W, Browne J, Egrie JC, Nissenson AR, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998; 339: 584-590. Ref.: https://goo.gl/ozUF3K
  12. Mahon A, Docherty B. Renal anaemia: the patient experience. Edtna Erca J. 2004; 30: 34-37. : https://goo.gl/hFfRvG
  13. Annual data report: atlas of end-stage renal disease in the United States. United States Renal Data System. 2007.
  14. Carrera F, Disney A, Molina M. Extended dosing intervals with erythropoiesis-stimulating agents in chronic kidney disease: a review of clinical data. Nephrol Dial Transplant. 2007; 22. : https://goo.gl/H6atrt
  15. Macdougall I. C.E.R.A., a once-monthly ESA: is it living up to expectations? Port J Nephrol Hypert. 2009; 23: 219-223. Ref.: https://goo.gl/ARyS17
  16. McMurray J, Parfrey P, Adamson J, et al. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl. 2012; 2: 1-335.
  17. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998; 339: 584-590. Ref.: https://goo.gl/WkHRnb
  18. Singh A, Szczech L, Tang KL, Barnhart H, Sapp S, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006; 355: 2085-2098. Ref.: https://goo.gl/hsSAow
  19. Pfeffer M, Burdmann E, Chen CY, Cooper ME, de Zeeuw D, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009; 361: 2019-2032. Ref.: https://goo.gl/qNeqUG
  20. Fernando C, Charmaine EL, Angel de F, Francesco Locatelli, Johannes F.E. Mann, et al. Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: arandomized comparative trial. Nephrol Dial Transplant. 2010; 25: 4009-4017. Ref.: https://goo.gl/HYd8db
  21. Collins A, Brenner R, Ofman JJ, Chi EM, Stuccio-White N, et al. Epoetin alfa use in patients with ESRD. An analysis of recent US prescribing patterns and hemoglobin outcomes. Am J Kidney Dis. 2005; 46: 481-488. Ref.: https://goo.gl/vUscs9


Figure 1

Figure 1

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More